Profile Image

Dr Kelly Kiejda

Research Fellow

School of Biomedical Sciences and Pharmacy (Medical Genetics)

Cancer crusader

Dr Kelly Avery-Kiejda hopes to improve diagnosis and treatment for breast cancer sufferers by identifying new biomarkers for the disease.

Kelly Avery-Kiejda in the laboratory 

A protein known as 'the guardian of the genome' has been a source of scientific fascination to molecular biologist Dr Kelly Avery-Kiejda for the past seven years. The P53 protein is so named for its ability to prevent the propagation of mutations that can lead to cancer.

P53 is a tumour suppressor, which can put the brakes on cancer by inhibiting the division of cells with DNA damage. But the protein is deactivated in many types of cancers, neutralising this powerful protection against the disease. Avery-Kiejda's research is focused on gaining a better understanding of the function of the protein and the factors that influence its activation.

Avery-Kiejda's first postdoctoral project in 2005 involved the investigation of isoforms (variants) of P53 and their links to chemotherapy resistance in melanoma. She is now applying that expertise to breast cancer research, looking specifically at the role the protein plays in the progression of advanced cancer, with the aim of developing a better method of diagnosing a cancer's potential to develop metastases.

"P53 isoforms were only discovered in 2005 and there is very little known about their role in breast cancer. We are one of the few groups studying that and, to my knowledge, unique in our emphasis on their role in promoting metastatic disease," Avery-Kiejda points out. "Breast cancer, or any cancer, essentially becomes incurable once a secondary cancer develops, so if we can identify markers that will indicate at an early stage whether a patient is more likely to develop a metastasis, then we can treat that patient differently from the outset."

In a related line of research, Avery-Kiejda is pursuing a project that could expand treatment options for women diagnosed with triple-negative forms of breast cancer, which are resistant to most conventional forms of hormone therapy. Since 2009, she has been a key researcher on a multi-site project funded by the National Breast Cancer Foundation (NBCF) analysing the expression of microRNAs. These small molecules are known to play a role in some cancers and can be used as a prognostic tool. In a novel finding, her team has identified a subset of 27 microRNAs that appear to be irregular in breast cancer patients who have developed lymph node metastases.

"This is a critical and very exciting finding because it means we may be able to use this information either to develop a treatment target or to diagnose secondary cancers earlier," Avery-Kiejda explains. "We have been looking at this specifically in triple-negative breast cancers but it may be applicable to others as well."

Avery-Kiejda's research has attracted the support of key cancer organisations, including Cure Cancer Australia, Cancer Australia and the Melanoma Institute Australia. Her affiliation with the University of Newcastle and the Hunter Medical Research Institute (HMRI) has opened collaborations with influential researchers such as the Australia and New Zealand Breast Cancer Trials Group research director Professor John Forbes and internationally recognised cancer geneticist Professor Rodney Scott.

"Everyone, myself included, knows someone who has been affected by cancer," she notes. "It has always been my dream to do something that will make a difference to patients by contributing to more effective treatment strategies."

Visit the Centre for Cancer

Visit the HMRI website

Kelly Avery-Kiejda in the laboratory

Cancer crusader

Dr Kelly Avery-Kiejda hopes to improve diagnosis and treatment for breast cancer sufferers by identifying new biomarkers for the disease.

Read more

Career Summary

Biography

Research Expertise
Kelly Avery-Kiejda's research interests are: - understanding the molecular mechanisms of cancer development and the resistance of cancer to treatment - understanding how p53 function becomes de-regulated in cancer, in particular, melanoma and breast cancer - the role of miRNAs in advanced breast cancer

Teaching Expertise
Dr Avery-Kiejda is a full-time research academic. Currently, Dr Avery-Kiejda is the mentor of an early career postdoctoral fellow and the supervisor of 4 PhD candidates. - She has been the primary and co-supervisor of 2 Honours students (received 1st class Honours). She was the sole supervisor of 3 undergraduate students for their 3rd year projects in the Biotechnology and Biomedical Science degree. She was a demonstrator for the subject Molecular Genetics (2000).

Administrative Expertise
Journal Peer Review - Reviewer for: Neoplasia, Clinical Cancer Research, Molecular Cancer Therapeutics, International Journal of Cancer, Clinical & Experimental Metastasis, BMC Cancer, Breast Cancer Research, Cell & Tissue Research, British Journal of Cancer Grant Peer review - Member of the Cancer Australia Grant Review Committee (2013) - External assessor for NHMRC project grant funding rounds (2011, 2012, 2014) - Assessor for the Hunter Translation Cancer Research Unit pilot project grant rounds (2012)



Qualifications

  • PhD (Medicine), University of Sydney
  • Bachelor of Science (Biotechnology)(Honours), University of Newcastle

Keywords

  • breast cancer
  • gene expression
  • miRNA
  • p53

Languages

  • English (Mother)

Fields of Research

Code Description Percentage
111201 Cancer Cell Biology 30
111203 Cancer Genetics 30
111299 Oncology and Carcinogenesis not elsewhere classified 40

Professional Experience

Academic appointment

Dates Title Organisation / Department
1/01/2013 -  Membership - Australian Society for Biochemistry and Molecular Biology Australian Society for Biochemistry and Molecular Biology
Australia
1/03/2012 - 1/03/2013 Hunter Translational Cancer Research Unit Fellow University of Newcastle
Australia
1/01/2012 - 31/12/2012 Membership - Organising committee for the 2012 ASMR Cocktail Party, Newcastle, NSW, Australia. Held on the 21st September,c Organising committee for the 2012 ASMR Cocktail Party, Newcastle, NSW, Australia. Held on the 21st September,
Australia
1/01/2012 - 31/12/2012 Membership - Organising committee for the 2012 5th Annual Hunter Cancer Research Symposium, Newcastle, NSW, Australia. Held on 2nd November 2012. Organising committee for the 2012 5th Annual Hunter Cancer Research Symposium, Newcastle, NSW, Australia. Held on 2nd November 2012.
Australia
1/01/2012 - 31/12/2013 Membership - Organising committee for the 2013 Translational Cancer Research Conference, Newcastle, Australia Organising committee for the 2013 Translational Cancer Research Conference, Newcastle, Australia
Australia
1/01/2012 -  Membership - Research Enabling Committee of the Hunter Translational Cancer Research Unit Research Enabling Committee of the Hunter Translational Cancer Research Unit
Australia
1/01/2012 - 31/12/2012 Conference Chair - Session chair at the 2012 5th Annual Hunter Cancer Research Symposium, Newcastle, NSW, Australia. Held on 2nd November 2012. Session chair at the 2012 5th Annual Hunter Cancer Research Symposium, Newcastle, NSW, Australia. Held on 2nd November 2012.
Australia
1/01/2012 -  Membership - Institutional Biosafety Committee Institutional Biosafety Committee
Australia
1/01/2012 -  Membership - The NHMRC Postdoctoral Reference Group The NHMRC Postdoctoral Reference Group
Australia
1/01/2012 - 31/12/2012 Membership - 2012 ASMR Gala Dinner Organising Committee, 7th June, Customs House, Newcastle 2012 ASMR Gala Dinner Organising Committee, 7th June, Customs House, Newcastle
Australia
1/01/2011 -  Membership - Hunter Medical Research Institute Disaster Sub-Plan Committee Hunter Medical Research Institute Disaster Sub-Plan Committee
Australia
1/01/2011 -  Membership - The Australian Microarray and Associated Technologies Association The Australian Microarray and Associated Technologies Association
Australia
1/01/2011 - 31/12/2011 Conference Chair - Session chair at the 2011 4th Annual Hunter Medical Research Institute Cancer Research Program Symposium, Newcastle, NSW, Australia. Held on 4th November, 2011. Session chair at the 2011 4th Annual Hunter Medical Research Institute Cancer Research Program Symposium, Newcastle, NSW, Australia. Held on 4th November, 2011.
Australia
1/01/2011 - 31/12/2011 Membership - Organising committee for the 4th Annual Hunter Medical Research Institute Cancer Research Program Symposium, Newcastle, NSW, Australia Organising committee for the 4th Annual Hunter Medical Research Institute Cancer Research Program Symposium, Newcastle, NSW, Australia
Australia
1/08/2005 - 1/09/2009 Cameron Melanoma Research Fellow Calvary Mater Newcastle Hospital
Australia
1/08/2005 - 1/09/2009 Postdoctoral Research Fellow University of Newcastle
School of Biomedical Sciences and Pharmacy
Australia
1/01/2001 - 31/12/2005 Membership - Australian Society for Medical Research (ASMR) Australian Society for Medical Research (ASMR)
Australia

Membership

Dates Title Organisation / Department
1/01/2013 - 31/12/2013 Membership - 2013 ASMR Gala Dinner Organising Committee, 6th June, Merewether Surfhouse, Newcastle 2013 ASMR Gala Dinner Organising Committee, 6th June, Merewether Surfhouse, Newcastle
Australia

Teaching appointment

Dates Title Organisation / Department
1/02/2000 - 1/06/2000 Laboratory Demonstrator University of Newcastle
School of Environmental and Life Sciences
Australia

Awards

Recipient

Year Award
2001 Australian Postgraduate Award
University of Sydney
2001 Millennium Foundation Stipend Enhancement Grant
Unknown

Recognition

Year Award
2012 Emerging research leaders program
University of Newcastle
1999 Deans Commendation List
University of Newcastle
1998 Most Outstanding Performance in the subject Cell and Molecular Biology
University of Newcastle

Research Award

Year Award
2010 HMRI PULSE Education Prize
Unknown
2006 HMRI Translational Cancer Research Conference Early Career Researcher Poster Award
Hunter Medical Research Institute

Invitations

Speaker

Year Title / Rationale
2015 The Delta-40p53 isoform in breast cancer- friend or foe?
Presented by Ms Brianna Morten on my behalf due to inability to fly because of late stage pregnancy
2015 The role of small p53 isoforms in breast cancer.
2012 MicroRNA expression profiling in triple-negative breast cancer.
Organisation: The 9th International RNAi, MicroRNAs and Single Cell Biology Meeting, 1st-2nd May, 2012, Boston
2012 Small p53 Isoforms- BIG Implications for Prognosis and Treatment Response in Cancer.
Organisation: 22nd Annual Queenstown Molecular Biology Meeting: Cancer Biology Satellite. 26-27th August, 2012, Queenstown
2011 MicroRNA expression profiling in triple-negative breast cancer
Organisation: Pharmacy Australia Centre of Excellence (PACE), School of Pharmacy, The University of Queensland Description: Invited to present my research at the Seminar series for Pharmacy Australia Centre of Excellence (PACE), School of Pharmacy, The University of Queensland, Woolloongabba, QLD. 28th April, 2011.
2008 Small isoforms of p53: Do they contribute to melanoma chemoresistance?
Organisation: Research Seminar Series for the Melanoma Foundation, 15th August 2008., Sydney, NSW
2006 The role of p53 variants in human melanoma
Organisation: The Melanoma and Skin Cancer Research Institute (MASCRI) Seminar Series, 20th October 2006, Sydne y, NSW
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Journal article (29 outputs)

Year Citation Altmetrics Link
2016 Bolton KA, Avery-Kiejda KA, Holliday EG, Attia J, Bowden NA, Scott RJ, 'A polymorphic repeat in the IGF1 promoter influences the risk of endometrial cancer.', Endocr Connect, 5 115-122 (2016) [C1]
DOI 10.1530/EC-16-0003
Co-authors John Attia, Liz Holliday, Nikola Bowden
2016 Morten BC, Wong-Brown MW, Scott RJ, Avery-Kiejda KA, 'The presence of the intron 3 16 bp duplication polymorphism of p53 (rs17878362) in breast cancer is associated with a low ¿40p53:p53 ratio and better outcome', Carcinogenesis, 37 81-86 (2016)

© The Author 2015. Published by Oxford University Press. All rights reserved.Breast cancer is the most common female cancer, but it has relatively low rates of p53 mutations, sug... [more]

© The Author 2015. Published by Oxford University Press. All rights reserved.Breast cancer is the most common female cancer, but it has relatively low rates of p53 mutations, suggesting other mechanisms are responsible for p53 inactivation. We have shown that the p53 isoform, ¿40p53, is highly expressed in breast cancer, where it may contribute to p53 inactivation. ¿40p53 can be produced by alternative splicing of p53 in intron 2 and this is regulated by the formation of G-quadruplex structures in p53 intron 3, from which the nucleotides forming these structures overlap with a common polymorphism, rs17878362. rs17878362 alters p53 splicing to decrease fully spliced p53 messenger RNA (mRNA) in vitro following ionizing radiation and this in turn alters ¿40p53:p53. Hence, the presence of rs17878362 may be important in regulating ¿40p53:p53 in breast cancer. This study aimed to determine if rs17878362 was associated with altered ¿40p53 and p53 expression and outcome in breast cancer. We sequenced p53 in breast tumours from 139 patients and compared this with ¿40p53 and p53 mRNA expression. We found that the ratio of ¿40p53:p53 was significantly lower in tumours homozygous for the polymorphic A2 allele compared with those who were wild-type (A1/A1). Furthermore, there was a lower proportion of breast cancers carrying the A2 allele from patients who subsequently developed metastasis compared with those that did not. Finally, we show that patients whose tumours carried the polymorphic A2 allele had significantly better disease-free survival. These results show that rs17878362 is associated with a low ¿40p53:p53 ratio in breast cancer and that this is associated with better outcome.

DOI 10.1093/carcin/bgv164
Co-authors Rodney Scott, Michelle Wong-Brown
2016 Bolton KA, Holliday EG, Attia J, Bowden NA, Avery-Kiejda KA, Scott RJ, 'A novel polymorphic repeat in the upstream regulatory region of the estrogen-induced gene EIG121 is not associated with the risk of developing breast or endometrial cancer', BMC Research Notes, 9 (2016)

© 2016 The Author(s).Background: The estrogen-induced gene 121 (EIG121) has been associated with breast and endometrial cancers, but its mechanism of action remains unknown. In a... [more]

© 2016 The Author(s).Background: The estrogen-induced gene 121 (EIG121) has been associated with breast and endometrial cancers, but its mechanism of action remains unknown. In a genome-wide search for tandem repeats, we found that EIG121 contains a short tandem repeat (STR) in its upstream regulatory region which has the potential to alter gene expression. The presence of this STR has not previously been analysed in relation to breast or endometrial cancer risk. Results: In this study, the lengths of this STR were determined by PCR, fragment analysis and sequencing using DNA from 223 breast cancer patients, 204 endometrial cancer patients and 220 healthy controls to determine if they were associated with the risk of developing breast or endometrial cancer. We found this repeat to be highly variable with the number of copies of the AG motif ranging from 27 to 72 and having a bimodal distribution. No statistically significant association was identified between the length of this STR and the risk of developing breast or endometrial cancer or age at diagnosis. Conclusions: The STR in the upstream regulatory region of EIG121 is highly polymorphic, but is not associated with the risk of developing breast or endometrial cancer in the cohorts analysed here. While this polymorphic STR in the regulatory region of EIG121 appears to have no impact on the risk of developing breast or endometrial cancer, its association with disease recurrence or overall survival remains to be determined.

DOI 10.1186/s13104-016-2086-3
Co-authors Nikola Bowden, John Attia, Rodney Scott, Liz Holliday
2015 Dun MD, Chalkley RJ, Faulkner S, Keene S, Avery-Kiejda KA, Scott RJ, et al., 'Proteotranscriptomic profiling of 231-BR breast cancer cells: Identification of potential biomarkers and therapeutic targets for brain metastasis', Molecular and Cellular Proteomics, 14 2316-2330 (2015) [C1]

© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.Brain metastases are a devastating consequence of cancer and currently there are no specific biomarkers... [more]

© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.Brain metastases are a devastating consequence of cancer and currently there are no specific biomarkers or therapeutic targets for risk prediction, diagnosis, and treatment. Here the proteome of the brain metastatic breast cancer cell line 231-BR has been compared with that of the parental cell line MDA-MB-231, which is also metastatic but has no organ selectivity. Using SILAC and nanoLC-MS/MS, 1957 proteins were identified in reciprocal labeling experiments and 1584 were quantified in the two cell lines. A total of 152 proteins were confidently determined to be up- or down-regulated by more than twofold in 231-BR. Of note, 112/152 proteins were decreased as compared with only 40/152 that were increased, suggesting that down-regulation of specific proteins is an important part of the mechanism underlying the ability of breast cancer cells to metastasize to the brain. When matched against transcriptomic data, 43% of individual protein changes were associated with corresponding changes in mRNA, indicating that the transcript level is a limited predictor of protein level. In addition, differential miRNA analyses showed that most miRNA changes in 231-BR were up- (36/45) as compared with down-regulations (9/45). Pathway analysis revealed that proteome changes were mostly related to cell signaling and cell cycle, metabolism and extracellular matrix remodeling. The major protein changes in 231-BR were confirmed by parallel reaction monitoring mass spectrometry and consisted in increases (by more than fivefold) in the matrix metalloproteinase-1, ephrin-B1, stomatin, myc target-1, and decreases (by more than 10-fold) in transglutaminase-2, the S100 calcium-binding protein A4, and L-plastin. The clinicopathological significance of these major proteomic changes to predict the occurrence of brain metastases, and their potential value as therapeutic targets, warrants further investigation.

DOI 10.1074/mcp.M114.046110
Citations Scopus - 2
Co-authors Rodney Scott, Hubert Hondermarck, Murray Cairns, Matt Dun
2015 Stirzaker C, Zotenko E, Song JZ, Qu W, Nair SS, Locke WJ, et al., 'Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value', Nature Communications, 6 1-11 (2015) [C1]
DOI 10.1038/ncomms6899
Citations Scopus - 11Web of Science - 1
Co-authors John Forbes, Rodney Scott
2015 Mathe A, Scott RJ, Avery-Kiejda KA, 'MiRNAs and other epigenetic changes as biomarkers in triple negative breast cancer', International Journal of Molecular Sciences, 16 28347-28376 (2015) [C1]

© 2015 by the authors; licensee MDPI, Basel, Switzerland.Triple negative breast cancer (TNBC) is characterised by the lack of receptors for estrogen (ER), progesterone (PR), and ... [more]

© 2015 by the authors; licensee MDPI, Basel, Switzerland.Triple negative breast cancer (TNBC) is characterised by the lack of receptors for estrogen (ER), progesterone (PR), and human epidermal growth factor 2 (HER2). Since it cannot be treated by current endocrine therapies which target these receptors and due to its aggressive nature, it has one of the worst prognoses of all breast cancer subtypes. The only treatments remain chemo- and/or radio-therapy and surgery and because of this, novel biomarkers or treatment targets are urgently required to improve disease outcomes. MicroRNAs represent an attractive candidate for targeted therapies against TNBC, due to their natural ability to act as antisense interactors and regulators of entire gene sets involved in malignancy and their superiority over mRNA profiling to accurately classify disease. Here we review the current knowledge regarding miRNAs as biomarkers in TNBC and their potential use as therapeutic targets in this disease. Further, we review other epigenetic changes and interactions of these changes with microRNAs in this breast cancer subtype, which may lead to the discovery of new treatment targets for TNBC.

DOI 10.3390/ijms161226090
Citations Scopus - 2
Co-authors Rodney Scott
2015 Mathe A, Wong-Brown M, Morten B, Forbes JF, Braye SG, Avery-Kiejda KA, Scott RJ, 'Novel genes associated with lymph node metastasis in triple negative breast cancer', Scientific Reports, 5 (2015) [C1]

Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype with the worst prognosis and no targeted treatments. TNBC patients are more likely to develop met... [more]

Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype with the worst prognosis and no targeted treatments. TNBC patients are more likely to develop metastases and relapse than patients with other breast cancer subtypes. We aimed to identify TNBC-specific genes and genes associated with lymph node metastasis, one of the first signs of metastatic spread. A total of 33 TNBCs were used; 17 of which had matched normal adjacent tissues available, and 15 with matched lymph node metastases. Gene expression microarray analysis was used to reveal genes that were differentially expressed between these groups. We identified and validated 66 genes that are significantly altered when comparing tumours to normal adjacent samples. Further, we identified 83 genes that are associated with lymph node metastasis and correlated these with miRNA-expression. Pathway analysis revealed their involvement in DNA repair, recombination and cell death, chromosomal instability and other known cancer-related pathways. Finally, four genes were identified that were specific for TNBC, of which one was associated with overall survival. This study has identified novel genes involved in LN metastases in TNBC and genes that are TNBC specific that may be used as treatment targets or prognostic indicators in the future.

DOI 10.1038/srep15832
Co-authors John Forbes, Rodney Scott, Michelle Wong-Brown
2014 Avery-Kiejda KA, Braye SG, Forbes JF, Scott RJ, 'The expression of Dicer and Drosha in matched normal tissues, tumours and lymph node metastases in triple negative breast cancer', BMC CANCER, 14 (2014) [C1]
DOI 10.1186/1471-2407-14-253
Citations Scopus - 12Web of Science - 7
Co-authors John Forbes, Rodney Scott
2014 Wong-Brown MW, Avery-Kiejda KA, Bowden NA, Scott RJ, 'Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer', International Journal of Cancer, 134 301-305 (2014) [C1]

Triple-negative breast cancer (TNBC) is a tumour classification that is defined by oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 receptor ... [more]

Triple-negative breast cancer (TNBC) is a tumour classification that is defined by oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 receptor negativity. TNBCs share a similar gene expression profile to BRCA-mutated tumours, have been shown to carry a high proportion of BRCA mutations and have a more adverse prognosis compared to other types of breast tumours. PALB2 has been shown to be a moderate-penetrance breast cancer susceptibility gene and is involved in the same DNA damage repair pathway as BRCA1 and BRCA2; this raises the possibility that germline PALB2 mutations may be involved in the pathogenesis of TNBCs. In our study, we sequenced the coding regions of PALB2 (including intron/exon boundaries) in genomic DNA from 347 patients diagnosed with TNBC to determine the prevalence of deleterious mutations in this population. Two novel truncating mutations (c.758dup and c.2390del) and one previously detected truncating mutation (c.3113+5G>C) were found. In addition, five variants predicted to be protein-affecting were also identified. Our study shows that the prevalence of PALB2 germline mutations in individuals with TNBC is ~1%, similar to the prevalence of PALB2 germline mutation of 1% in familial non-BRCA1/2 breast cancer cohorts. © 2013 UICC.

DOI 10.1002/ijc.28361
Citations Scopus - 4Web of Science - 3
Co-authors Michelle Wong-Brown, Rodney Scott, Nikola Bowden
2014 Avery-Kiejda KA, Braye SG, Mathe A, Forbes JF, Scott RJ, 'Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer', BMC Cancer, 14 (2014) [C1]

Background: Breast cancer is the most common malignancy that develops in women, responsible for the highest cancer-associated death rates. Triple negative breast cancers represent... [more]

Background: Breast cancer is the most common malignancy that develops in women, responsible for the highest cancer-associated death rates. Triple negative breast cancers represent an important subtype that have an aggressive clinical phenotype, are associated with a higher likelihood of metastasis and are not responsive to current targeted therapies. miRNAs have emerged as an attractive candidate for molecular biomarkers and treatment targets in breast cancer, but their role in the progression of triple negative breast cancer remains largely unexplored.Methods: This study has investigated miRNA expression profiles in 31 primary triple negative breast cancer cases and in 13 matched lymph node metastases compared with 23 matched normal breast tissues to determine miRNAs associated with the initiation of this disease subtype and those associated with its metastasis.Results: 71 miRNAs were differentially expressed in triple negative breast cancer, the majority of which have previously been associated with breast cancer, including members of the miR-200 family and the miR-17-92 oncogenic cluster, suggesting that the majority of miRNAs involved in the initiation of triple negative breast cancer are not subtype specific. However, the repertoire of miRNAs expressed in lymph node negative and lymph node positive triple negative breast cancers were largely distinct from one another. In particular, miRNA profiles associated with lymph node negative disease tended to be up-regulated, while those associated with lymph node positive disease were down-regulated and largely overlapped with the profiles of their matched lymph node metastases. From this, 27 miRNAs were identified that are associated with metastatic capability in the triple negative breast cancer subtype.Conclusions: These results provide novel insight into the repertoire of miRNAs that contribute to the initiation of and progression to lymph node metastasis in triple negative breast cancer and have important implications for the treatment of this breast cancer subtype. © 2014 Avery-Kiejda et al.; licensee BioMed Central Ltd.

DOI 10.1186/1471-2407-14-51
Citations Scopus - 18Web of Science - 9
Co-authors John Forbes, Rodney Scott
2014 Avery-Kiejda KA, Morten B, Wong-Brown MW, Mathe A, Scott RJ, 'The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome.', Carcinogenesis, 35 586-596 (2014) [C1]
DOI 10.1093/carcin/bgt411
Citations Scopus - 9Web of Science - 4
Co-authors Michelle Wong-Brown, Rodney Scott
2013 Bolton KA, Ross JP, Grice DM, Bowden NA, Holliday EG, Avery-Kiejda KA, Scott RJ, 'STaRRRT: a table of short tandem repeats in regulatory regions of the human genome', BMC GENOMICS, 14 (2013) [C1]
DOI 10.1186/1471-2164-14-795
Citations Scopus - 8Web of Science - 6
Co-authors Liz Holliday, Rodney Scott, Nikola Bowden
2013 Bowden NA, Ashton KA, Vilain RE, Avery-Kiejda KA, Davey RJ, Murray HC, et al., 'Regulators of Global Genome Repair Do Not Respond to DNA Damaging Therapy but Correlate with Survival in Melanoma', PLOS ONE, 8 (2013) [C1]
DOI 10.1371/journal.pone.0070424
Citations Scopus - 1Web of Science - 1
Co-authors Xu Zhang, Rodney Scott, Katie Ashton, Nikola Bowden
2011 Kiejda KA, Bowden NA, Croft AJ, Scurr LL, Kairupan CF, Ashton KA, et al., 'P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation', BMC Cancer, 11 203-219 (2011) [C1]
DOI 10.1186/1471-2407-11-203
Citations Scopus - 38Web of Science - 22
Co-authors Nikola Bowden, Katie Ashton, Bente Talseth-Palmer, Rodney Scott, Xu Zhang
2011 Kiejda KA, Wong-Brown M, Scott R, 'Genetic markers in breast cancer - How far have we come from BRCA1?', Asia-Pacific Journal of Molecular Medicine, 1 1-15 (2011) [C1]
Co-authors Rodney Scott, Michelle Wong-Brown
2011 Wong-Brown M, Nordfors C, Mossman D, Pecenpetelovska G, Kiejda KA, Talseth-Palmer B, et al., 'BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer', Breast Cancer Research and Treatment, 127 853-859 (2011) [C1]
DOI 10.1007/s10549-011-1443-0
Citations Scopus - 57Web of Science - 40
Co-authors Nikola Bowden, Rodney Scott, Michelle Wong-Brown, Bente Talseth-Palmer
2010 Bowden NA, Ashton KA, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Nucleotide excision repair gene expression after cisplatin treatment in melanoma', Cancer Research, 70 7918-7926 (2010) [C1]
Citations Scopus - 10Web of Science - 7
Co-authors Katie Ashton, Rodney Scott, Xu Zhang, Nikola Bowden
2009 Jiang CC, Mao ZG, Kiejda KA, Hersey P, Zhang XD, 'Glucose-regulated protein 78 antagonizes cisplatin and adriamycin in human melanoma cells', Carcinogenesis, 30 197-204 (2009) [C1]
DOI 10.1093/carcin/bgn220
Citations Scopus - 51Web of Science - 45
Co-authors Chenchen Jiang, Xu Zhang
2008 Kiejda KA, Zhang XD, Adams LJ, Scott R, Vojtesek B, Lane DP, Hersey P, 'Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin', Clinical Cancer Research, 14 1659-1668 (2008) [C1]
DOI 10.1158/1078-0432.ccr-07-1422
Citations Scopus - 57Web of Science - 46
Co-authors Xu Zhang, Rodney Scott
2008 Chen LH, Jiang CC, Watts R, Thorne RF, Kiejda KA, Zhang XD, Hersey P, 'Inhibition of endoplasmic reticulum stress-induced apoptosis of melanoma cells by the ARC protein', Cancer Research, 68 834-842 (2008) [C1]
DOI 10.1158/0008-5472.can-07-5056
Citations Scopus - 30Web of Science - 24
Co-authors Xu Zhang, Rick Thorne, Chenchen Jiang
2008 Jiang CC, Lucas K, Kiejda KA, Wade M, Debock CE, Thorne RF, et al., 'Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress', Cancer Research, 68 6708-6717 (2008) [C1]
DOI 10.1158/0008-5472.can-08-0349
Citations Scopus - 81Web of Science - 73
Co-authors Chenchen Jiang, Rick Thorne, Xu Zhang
2008 Zhu B-K, Wang P, Zhang XD, Jiang CC, Chen LH, Kiejda KA, et al., 'Activation of Jun N-terminal kinase is a mediator of vincristine-induced apoptosis of melanoma cells', Anti-Cancer Drugs, 19 189-200 (2008) [C1]
DOI 10.1097/CAD.0b013e3282f3138a
Citations Scopus - 24Web of Science - 22
Co-authors Chenchen Jiang, Xu Zhang
2007 Yu FW, Jiang CC, Kiejda KA, Gillespie S, Zhang XD, Hersey P, 'Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1', Clinical Cancer Research, 13 4934-4942 (2007) [C1]
DOI 10.1158/1078-0432.CCR-07-0665
Citations Scopus - 107Web of Science - 110
Co-authors Chenchen Jiang, Xu Zhang
2007 Mhaidat NM, Wang Y, Kiejda KA, Zhang XD, Hersey P, 'Docetaxel-induced apoptosis in melanoma cells is dependent on activation of caspase-2', Molecular Cancer Therapeutics, 6 752-761 (2007) [C1]
DOI 10.1158/1535-7163.MCT-06-0564
Citations Scopus - 58Web of Science - 48
Co-authors Xu Zhang
2007 Mhaidat NM, Zhang XD, Allen J, Kiejda KA, Scott R, Hersey P, 'Temozolomide induces senescence but not apoptosis in human melanoma cells', British Journal of Cancer, 97 1225-1233 (2007) [C1]
DOI 10.1038/sj.bjc.6604017
Citations Scopus - 39Web of Science - 36
Co-authors Rodney Scott, Xu Zhang
2007 Jiang CC, Li HC, Gillespie S, Kiejda KA, Mhaidat N, Yu FW, et al., 'Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response', Cancer Research, 67 5880-5888 (2007) [C1]
DOI 10.1158/0008-5472.CAN-07-0213
Citations Scopus - 70Web of Science - 65
Co-authors Rick Thorne, Xu Zhang, Chenchen Jiang
2007 Jiang CC, Li HC, Gillespie S, Yu FW, Kiejda KA, Zhang XD, Hersey P, 'Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosis', Cancer Research, 67 9750-9761 (2007) [C1]
DOI 10.1158/0008-5472.CAN-07-2047
Citations Scopus - 90Web of Science - 78
Co-authors Chenchen Jiang, Xu Zhang
2007 Chen LH, Jiang CC, Kiejda KA, Wang YF, Thorne RF, Zhang XD, Hersey P, 'Thapsigargin sensitizes human melanoma cells to TRAIL-induced apoptosis by up-regulation of TRAIL-R2 through the unfolded protein response', Carcinogenesis, 28 2328-2336 (2007) [C1]
DOI 10.1093/carcin/bgm173
Citations Scopus - 31Web of Science - 26
Co-authors Xu Zhang, Rick Thorne, Chenchen Jiang
2004 Mote PA, Leary JA, Avery KA, Sandelin K, Chenevix-Trench G, Kirk JA, Clarke CL, 'Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A. Genes Chromosomes Cancer 2004;39:236-48. (2004) [C1]
Show 26 more journal articles

Conference (71 outputs)

Year Citation Altmetrics Link
2015 Morten B, Wong-Brown M, Scott R, Avery-Kiejda K, 'ASSOCIATION OF THE POLYMORPHIC INTRON 3 16 BP DUPLICATION IN TP53 (RS17878362) WITH A LOW Delta 40P53:P53 RATIO AND BETTER OUTCOME IN BREAST CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors Michelle Wong-Brown, Rodney Scott
2014 Morten B, Campbell HG, Brown MW, Mathe A, Braithwaite AW, Scott RJ, Kiejda KA, '¿40p53 regulation of estrogen responsiveness in breast cancer.', 16th International p53 Workshop Proceedings (2014) [E3]
Co-authors Rodney Scott, Michelle Wong-Brown
2014 Morten B, Scott RJ, Avery-Kiejda KA, 'Comparison of the Quantigene 2.0 Assay for the detection of p53 isoform mRNA expression in FFPE tissues.', 16th International p53 Workshop Proceedings (2014) [E3]
2014 Morten B, Scott RJ, Kiejda KA, 'The role of ¿40p53 and p53 in Estrogen-Receptor-a signaling pathways in breast cancer.', 23rd Biennial Congress of the European Association for Cancer Research Proceedings Book (2014) [E3]
Co-authors Rodney Scott
2014 Morten B, Campbell HG, Wong-Brown MW, Mathe A, Braithwaite AW, Scott RJ, Avery-Kiejda KA, 'Delta-40P53 regulation of ERa-mediated signalling in breast cancer.', The 29th International Association for Breast Cancer Research Conference Proceedings (2014) [E3]
Co-authors Rodney Scott
2014 Mathe A, Avery-Kiejda KA, Wong-Brown M, Forbes JF, Braye SG, Scott RJ, 'Can microRNAs impact cell migration in triple negative breast cancer?', The Australian Society for Medical Research (ASMR) Satellite Scientific Meeting Programme (2014) [E3]
Co-authors Rodney Scott, John Forbes
2014 Morten B, Scott RJ, Avery-Kiejda KA, '¿40p53 and p53 mediate ER-a expression in breast cancer cells.', The Australian Society for Medical Research (ASMR) Satellite Scientific Meeting Programme (2014) [E3]
Co-authors Rodney Scott
2014 Avery-Kiejda KA, Morten B, Wong-Brown MW, Mathe A, Scott RJ, 'The relationship between p53 isoforms and prognosis in breast cancer.', The Australian Society for Medical Research (ASMR) Satellite Scientific Meeting Programme (2014) [E3]
Co-authors Michelle Wong-Brown, Rodney Scott
2014 Bolton KA, Ross JP, Grice DM, Bowden NA, Holliday EG, Kiejda KA, Scott RJ, 'Short tandem repeats are variable genetic elements that may have major consequences for multiple diseases.', The Australian Society for Medical Research (ASMR) Satellite Scientific Meeting Programme (2014) [E3]
Co-authors Nikola Bowden, Rodney Scott, Liz Holliday
2014 Mathe A, Avery-Kiejda KA, Wong-Brown M, Morten B, Forbes JF, Braye SG, Scott RJ, 'IDENTIFICATION OF NOVEL TRANSCRIPTS SPECIFIC TO TRIPLE NEGATIVE BREAST CANCER THAT ARE ASSOCIATED WITH LYMPH NODE METASTASIS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
DOI 10.1111/ajco.12335
Co-authors Michelle Wong-Brown, Rodney Scott, John Forbes
2014 Morten B, Scott RJ, Avery-Kiejda KA, 'Delta 40P53 CAN ALTER BREAST CANCER CELL GROWTH BY MEDIATING THE ESTROGEN RESPONSE', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Rodney Scott
2014 Mathe A, Avery-Kiejda KA, Wong-Brown M, Forbes JF, Braye SG, Scott RJ, 'Eight microRNAs as biomarkers for metastatic spread in triple negative breast cancer', EUROPEAN JOURNAL OF CANCER (2014) [E3]
Co-authors John Forbes, Michelle Wong-Brown, Rodney Scott
2014 Morten B, Scott RJ, Avery-Kiejda KA, 'The role of Delta-40p53 and p53 in Estrogen Receptor-alpha signalling pathways in breast cancer', EUROPEAN JOURNAL OF CANCER (2014) [E3]
Co-authors Rodney Scott
2014 Bolton KA, Holliday EG, Bowden NA, Avery-Kiejda KA, Scott RJ, 'A highly polymorphic AG repeat in the upstream regulatory region of the estrogen-induced gene EIG121 is a modifier of disease risk in endometrial cancer', EUROPEAN JOURNAL OF CANCER (2014) [E3]
Co-authors Nikola Bowden, Liz Holliday, Rodney Scott
2014 Bolton KA, Holliday EG, McEvoy M, Attia J, Proietto A, Otton G, et al., 'A highly polymorphic AG repeat in the upstream regulatory region of the estrogen gene EIG121 is a potential modifier of endometrial cancer risk.', Asia-Pacific Journal of Clinical Oncology (2014) [E3]
DOI 10.1111/ajco.12335
Co-authors Rodney Scott, John Attia, Mark Mcevoy, Liz Holliday, Nikola Bowden
2013 Zotenko E, Stirzaker C, Song JZ, Qu W, Nair S, Avery-Kiejda KA, et al., 'Genome-wide DNA methylation analysis of archival formalin-fixed paraffin-embedded tissue (FFPET) using MDBCAP-Seq identifies novel epigenetic diagnostic biomarker loci in breast cancer.', 25th Lorne Cancer Conference Proceedings (2013) [E3]
Co-authors Rodney Scott
2013 Morten B, Mathe A, Scott RJ, Avery-Kiejda KA, 'mRNA expression analysis of p53 isoforms in breast cancer.', 25th Lorne Cancer Conference Proceedings (2013) [E3]
Co-authors Rodney Scott
2013 Avery-Kiejda KA, Mathe A, Braye SG, Forbes JF, Scott RJ, 'The expression of Dicer and Drosha in lymph node metastases of triple negative breast cancer.', 25th Lorne Cancer Conference Proceedings (2013) [E3]
Co-authors Rodney Scott, John Forbes
2013 Mathe A, Avery-Kiejda KA, Wong-Brown MW, Forbes JF, Braye SG, Scott RJ, 'Target gene identification of microRNAs associated with lymph node metastases in triple negative breast cancer.', 25th Lorne Cancer Conference Proceedings (2013) [E3]
Co-authors John Forbes, Michelle Wong-Brown, Rodney Scott
2013 Bolton KA, Ross J, Grice DM, Avery-Kiejda KA, Bowden NA, Holliday EG, Scott RJ, 'Role of Short Tandem Repeats in Disease and Evolutionary Mechanisms.', 34th Lorne Genome Conference Proceedings (2013) [E3]
Co-authors Nikola Bowden, Liz Holliday, Rodney Scott
2013 Mathe A, Avery-Kiejda KA, Wong-Brown M, Forbes JF, Braye SG, Scott RJ, 'Integration of microRNA and gene expression profiling in triple negative breast cancer to identify possible biomarkers for metastases.', Breakthrough Breast Cancer TNBC Conference Proceedings (2013) [E3]
Co-authors Michelle Wong-Brown, John Forbes, Rodney Scott
2013 Wong-Brown M, Li S, Wilkins M, Avery-Kiejda KA, Bowden N, Scott R, 'Targeted resequencing of BRCA1 and BRCA2 in familial breast cancer.', Kathleen Cunningham Foundation Consortium for Research into Familial Aspects of Cancer 2013 Research and Practice Proceedings (2013) [E3]
Co-authors Nikola Bowden, Rodney Scott, Michelle Wong-Brown
2013 Wong-Brown M, Avery-Kiejda K, Bowden N, Scott R, 'Prevalence of BRCA1 and BRCA2 germline mutations in triple-negative breast cancer', Programme (2013) [E3]
Citations Web of Science - 3
Co-authors Michelle Wong-Brown, Rodney Scott, Nikola Bowden
2013 Morten B, Scott RJ, Avery-Kiejda KA, 'Microarray analysis of differentially expressed genes in patients with high ¿40p53 expression.', Translational Cancer Research Conference Abstract booklet (2013) [E3]
Co-authors Rodney Scott
2013 Bolton KA, Avery-Kiejda KA, Grice DM, Holliday EG, Bowden NA, Ross J, Scott RJ, 'STaRRRT: Our new resource for identifying candidates of genetic risk in breast and endometrial cancer.', Translational Cancer Research Conference Abstract booklet (2013) [E3]
Co-authors Liz Holliday, Rodney Scott, Nikola Bowden
2013 Mathe A, Wong-Brown M, Forbes JF, Braye SG, Scott RJ, Avery-Kiejda KA, 'Identification of biomarkers for metastatic spread in triple negative breast cancer.', Translational Cancer Research Conference Abstract booklet (2013) [E3]
Co-authors Michelle Wong-Brown, Rodney Scott, John Forbes
2012 Bolton KA, Ross J, Grice DM, Kiejda KA, Bowden NA, Holliday EG, Scott R, 'Potential role of short tandem repeats in disease processes', Abstracts. 6th Australian Health & Medical Research Congress (2012) [E3]
Co-authors Nikola Bowden, Liz Holliday, Rodney Scott
2012 Kiejda KA, Forbes JF, Braye SG, Scott R, 'Identification of miRNAs associated with lymph node metastasis in triple-negative breast cancer', Human Genome Meeting 2012: Genetics and Genomics in Personalised Medicine. Abstract Book (2012) [E3]
Co-authors John Forbes, Rodney Scott
2012 Wong-Brown M, Li S, Wilkins M, Kiejda KA, Bowden NA, Scott R, 'Exploratory targeted resequencing of BRCA1 and BRCA2 in inherited breast cancer', Programme. kConFab Familial Aspects of Cancer: Research & Practice 2012 (2012) [E3]
Co-authors Nikola Bowden, Rodney Scott, Michelle Wong-Brown
2012 Wong-Brown M, Li S, Wilkins M, Kiejda KA, Bowden NA, Scott R, 'Targeted resequencing of BRCA1 and BRCA2 in inherited breast cancer', Cancer Research (2012) [E3]
Co-authors Nikola Bowden, Michelle Wong-Brown, Rodney Scott
2012 Avery-Kiejda KA, Forbes JF, Braye SG, Scott RJ, 'Can Dicer explain decreased microRNA expression in lymph node metastases of triple negative breast cancer?', 14th International Biennial Congress of the Metastasis Research Society Delegate Handbook (2012)
2012 Bowden NA, Ashton KA, Villain RE, Braye SG, Avery-Kiejda KA, Zhang XD, et al., 'Regulators of DNA repair do not respond to DNA damaging therapy but correlate with survival in melanoma.', 5th Annual Hunter Cancer Research Symposium Programme (2012)
2012 Wong-Brown M, Li S, Wilkins M, Avery-Kiejda KA, Bowden NA, Scott RJ, 'Targeted resequencing of BRCA1 and BRCA2 in inherited breast cancer.', 5th Annual Hunter Cancer Research Symposium Programme (2012)
2012 Avery-Kiejda KA, Forbes JF, Braye SG, Scott RJ, 'The expression of key tumour suppressor microRNAs is decreased in lymph-node positive triple-negative breast cancer.', 5th Annual Hunter Cancer Research Symposium Programme (2012)
2012 Morten B, Scott RJ, Avery-Kiejda KA, 'p53 isoform expression is correlated with ER-alpha expression in breast cancer.', 5th Annual Hunter Cancer Research Symposium Programme (2012)
2012 Bolton KA, Ross JP, Grice DM, Avery-Kiejda KA, Bowden NA, Holliday EG, Scott RJ, 'Short Tandem Repeats in Regulatory Regions of Human Genes: Where, What, How and Why??', 5th Annual Hunter Cancer Research Symposium Programme (2012)
2012 Mathe A, Avery-Kiejda KA, Forbes JF, Braye SG, Scott RJ, 'The functional role of microRNAs associated with lymph node metastases in triple negative breast cancer.', 5th Annual Hunter Cancer Research Symposium Programme (2012)
2012 Avery-Kiejda KA, Forbes JF, Braye SG, Scott RJ, 'MicroRNA expression profiling in triple-negative breast cancer.', RNAi, MicroRNAs and Single Cell Biology and Stem Cells 2012- Boston Metting Proceedings (2012)
2012 Avery-Kiejda KA, Morten B, Scott RJ, 'The expression of p53 isoforms in breast cancer.', The First Australian p53 Workshop Programme (2012)
2012 Morten B, Scott RJ, Avery-Kiejda KA, 'p53 isoforms and estrogen responsiveness in breast cancer.', The First Australian p53 Workshop Programme (2012)
2011 Bowden NA, Ashton KA, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Downstream effects of reduction in nucleotide excision repair in response to cisplatin treatment in melanoma', Pigment Cell & Melanoma Research (2011) [E3]
DOI 10.1111/j.1755-148X.2011.00909.x
Co-authors Xu Zhang, Rodney Scott, Katie Ashton, Nikola Bowden
2011 Kiejda KA, Forbes JF, Hope TL, Braye SG, Scott R, 'Differential expression of miRNAs in triple-negative breast cancer', AMATA Conference Canberra 2011 Handbook (2011) [E3]
Co-authors Rodney Scott, John Forbes
2011 Kiejda KA, Forbes JF, Braye SG, Scott R, 'MicroRNA expression profiling in triple-negative breast cancer', Keystone Symposia on Mollecular and Cellular Biology: MicroRNAs and Non-coding RNAs and Cancer (2011) [E3]
Co-authors Rodney Scott, John Forbes
2011 Avery-Kiejda KA, 'Cancer research at the Centre for Information-Based Medicine.', Hunter Medical Research Institute (HMRI) Cancer Research Program Symposium Proceedings (2011)
2010 Croft AJ, Kiejda KA, Bowden NA, Zhang X, Scott R, Hersey P, 'Expression profiling on apoptosis-related genes in cisplatin-treated human melanoma cell lines', 22nd Lorne Cancer Conference: Abstracts and Delegate Information (2010) [E3]
Co-authors Rodney Scott, Nikola Bowden
2010 Wong-Brown M, Bowden NA, Kiejda KA, Scott R, 'BRIP1 and PALB2 mutation detection in Hunter-New England familial breast cancer cohort', 27th HUGO-IABCR Congress 2010. Genomics, Biology and Breast Cancer Treatment. Programme & Abstract Book (2010) [E3]
Co-authors Rodney Scott, Michelle Wong-Brown, Nikola Bowden
2010 Bowden NA, Ashton KA, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Altered nucleotide excision repair gene expression after cisplatin treatment in melanoma', AACR 101st Annual Meeting 2010. Abstracts (2010) [E3]
DOI 10.1158/0008-5472.CAN-10-0161
Co-authors Xu Zhang, Rodney Scott, Katie Ashton, Nikola Bowden
2010 Ashton KA, Bowden NA, Kairupan CF, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Base excision repair and gene expression profiling in malignant melanoma', Sydney Cancer Conference 2010. Profiling Risk, Personalising Treatment and Predicting Outcomes. Conference Program and Abstract Book (2010) [E3]
Co-authors Katie Ashton, Nikola Bowden, Xu Zhang, Rodney Scott
2010 Kiejda KA, Forbes JF, Braye SG, Scott R, 'The relationship between p53 isofor and estrogen receptor-alpha expression in breast cancer', Sydney Cancer Conference 2010. Profiling Risk, Personalising Treatment and Predicting Outcomes. Conference Program and Abstract Book (2010) [E3]
Co-authors Rodney Scott, John Forbes
2010 Ashton KA, Bowden NA, Vilain RE, Kairupan CF, Kiejda KA, Zhang XD, et al., 'Genetic variation of the base excision repair gene, MUTYH, and melanoma development', Melanoma 2010 Congress. Oral and Poster Abstracts (2010) [E3]
Co-authors Nikola Bowden, Xu Zhang, Katie Ashton
2010 Bowden NA, Ashton KA, Kiejda KA, Vilain RE, Braye SG, Kairupan CF, et al., 'Nucleotide excision repair gene expression in melanoma', Melanoma 2010 Congress. Oral and Poster Abstracts (2010) [E3]
DOI 10.1158/0008-5472.CAN-10-0161
Co-authors Katie Ashton, Nikola Bowden, Xu Zhang
2009 Kiejda KA, Scurr LL, Wade MA, Jiang CC, Weir AJW, Bowden NA, et al., 'Cisplatin induces apoptosis independently of Noxa or PUMA in human melanoma cells', 21st Lorne Cancer Conference (2009) [E3]
Co-authors Nikola Bowden, Rodney Scott, Chenchen Jiang, Xu Zhang
2009 Zhang XD, Jiang CC, Kiejda KA, Hersey P, 'Up-regulation of Mcl-1 by the unfolded protein response is critical for survival of melanoma cells upon ER stress', 7th World Congress on Melanoma, 5th Congress of the European Association of Dermato-Oncology (EADO): Final Program (2009) [E3]
Co-authors Xu Zhang
2008 Bowden NA, Ashton KA, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Altered nucleotide excision repair gene expression after cisplatin treatment in melanoma', Proceedings of the Australian Health and Medical Research Congress 2008 (2008) [E3]
Co-authors Xu Zhang, Rodney Scott, Nikola Bowden, Katie Ashton
2008 Zhang XD, Jiang CC, Avery-Kiejda KA, Lucas K, Wade M, Allen J, Hersey P, 'Up-regulation of Mcl-1 by the unfolded protein response is critical for survival of melanoma cells upon ER stress', PIGMENT CELL & MELANOMA RESEARCH (2008) [E3]
Co-authors Chenchen Jiang, Xu Zhang
2008 Kiejda KA, Zhang XD, Adams LJ, Scott R, Vojtesek B, Lane DP, Hersey P, 'The P53 splice variants, P53B and 40P53, are expressed in human melanoma cells and can differnetially regulate the transcription of P53 target genes in response to cisplatin', 20th Lorne Cancer Conference (2008) [E3]
Co-authors Rodney Scott, Xu Zhang
2008 Jiang CC, Wade MA, Kiejda KA, Wang Y, Zhang XD, Hersey P, 'Up-regulation of MCL-1 is critical for survival of human melanoma cells upon ER stress', 20th Lorne Cancer Conference (2008) [E3]
Co-authors Xu Zhang, Chenchen Jiang
2008 Zhang XD, Jiang CC, Wang YF, Kiejda KA, Hersey P, 'The MEK/ERK pathway potentiates adaptation of human melanoma to endoplasmic reticulum stress', 20th Lorne Cancer Conference (2008) [E3]
Co-authors Chenchen Jiang, Xu Zhang
2007 Jiang CC, Chen IH, Kiejda KA, Gillespie SK, Hersey P, Zhang XD, 'The unfolded protein response induced by tunicamycin or thapsigargin sensitizes human melanoma cells to trail-induced apoptosis by selective up-regulaton of trail-R2 on te cell surface', 19th Lorne Cancer Conference (2007) [E3]
Co-authors Xu Zhang, Chenchen Jiang
2007 Kiejda KA, Zhang XD, Hersey P, 'The P53 splice variant, P53B, is widely expressed in human melanoma', 19th Lorne Cancer Conference (2007) [E3]
Co-authors Xu Zhang
2007 Zhang XD, Jiang CC, Wang YF, Kiejda KA, Gillespie SK, Hersey P, 'Regulation of the BCL-2 family members BIM, PUMA and MCL-1 by MEK/ERK signaling plays a critical role in survival of melanoma cells', 19th Lorne Cancer Conference (2007) [E3]
Co-authors Xu Zhang, Chenchen Jiang
2007 Kiejda KA, Zhang XD, Adams LJ, Scott R, Vojtesek B, Lane DP, Hersey P, 'MEK/ERK-mediated regulation of the Bcl-2 family members Mcl-1, PUMA, and Bim contributes to survival of human melanoma cells', 4th Garvan Signalling Symposium. Conference Proceedings (2007) [E3]
Co-authors Rodney Scott, Xu Zhang
2007 Kiejda KA, Zhang XD, Adams LJ, Scott R, Vojtesek B, Lane DP, Hersey P, 'Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by cisplatin', 4th Garvan Signalling Symposium. Conference Proceedings (2007) [E3]
Co-authors Xu Zhang, Rodney Scott
2007 Zhang XD, Jiang CC, Wang YF, Kiejda KA, Hersey P, 'The MEK-ERK pathway potentiates adaptation of melanoma to endoplasmic reticulum stress', 4th Garvan Signalling Symposium. Conference Proceedings (2007) [E3]
Co-authors Xu Zhang, Chenchen Jiang
2007 Jiang CC, Wang YF, Kiejda KA, Gillespie SK, Zhang XD, Hersey P, 'Regulation of the Bcl-2 family members Bim, PUMA and Mcl-1 by MEK/ERK signaling plays a critical role in survival of melanoma cells', AACR Meeting Abstracts Online (Abstracts of the 98th AACR Annual Meeting) (2007) [E3]
Co-authors Xu Zhang, Chenchen Jiang
2006 Kiejda KA, Zhang XD, Hersey P, 'p53 variants in human melanoma', 13th Annual p53 Workshop. Program & Abstracts (2006) [E3]
Co-authors Xu Zhang
2006 Jiang CC, Wang YF, Kiejda KA, Zhang XD, Hersey P, 'CD133, A potential marker for cancer stem cells in melanoma', HMRI Conference on Translational Cancer Research. Molecular Mechanisms and Implications for Treatment (2006) [E3]
Co-authors Chenchen Jiang, Xu Zhang
2006 Kiejda KA, Zhang XD, Hersey P, 'Expression of P53 variants in human melanoma', HMRI Conference on Translational Cancer Research. Molecular Mechanisms and Implications for Treatment (2006) [E3]
Co-authors Xu Zhang
2006 Wang YF, Jiang CC, Kiejda KA, Zhang XD, Hersey P, 'Suppression of the BH3-only proteins BUM and PUMA by MEK/ERK signaling plays a crucial role in maintaining survival of melanoma cells', HMRI Conference on Translational Cancer Research. Molecular Mechanisms and Implications for Treatment (2006) [E3]
Co-authors Chenchen Jiang, Xu Zhang
2004 Avery KA, Graham JD, Defazio A, Clarke CL, 'Co-localisation of the progesterone receptor with BRCA1 in human breast cancer cells' (2004) [E3]
2004 Avery KA, Graham JD, Defazio A, Clarke CL, 'Endogenous levels of BRCA1 regulate progestin signalling' (2004) [E3]
Show 68 more conferences
Edit

Grants and Funding

Summary

Number of grants 27
Total funding $1,820,479

Click on a grant title below to expand the full details for that specific grant.


20161 grants / $23,750

Circulating exosomes in pancreatic cancer as a source of novel diagnostic biomarkers$23,750

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Associate Professor Christopher Scarlett, Doctor Jude Weidenhofer, Doctor Kelly Kiejda
Scheme Project Grant
Role Investigator
Funding Start 2016
Funding Finish 2016
GNo G1601070
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

20154 grants / $450,805

The Hunter Cancer Biobank (HCB): Maximising community value through validation, annotation and distribution throughout NSW$300,000

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Professor John Forbes, Conjoint Professor Stephen Ackland, Professor Rodney Scott, Professor Marjorie Walker, Professor Xu Dong Zhang, Doctor Pradeep Tanwar, Doctor Nikola Bowden, Doctor Craig Gedye, Doctor James Lynam, Doctor Kelly Kiejda, Doctor Jennette Sakoff, Mr Loui Rassam, Dr Tara Roberts, Professor Soon Lee, Dr Betty Kan
Scheme Research Infrastructure Grants
Role Investigator
Funding Start 2015
Funding Finish 2018
GNo G1500825
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Live cell imager for enhancement of pre-clinical cancer studies in the Hunter Translational Cancer Research Centre$124,938

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Conjoint Professor Stephen Ackland, Doctor Kelly Kiejda, Associate Professor Kevin Spring, Professor Xu Dong Zhang, Associate Professor Deborah Marsh, Associate Professor Christopher Scarlett, Doctor Pradeep Tanwar, Doctor Kathryn Skelding, Doctor Rick Thorne, Doctor Nikola Bowden
Scheme Research Equipment Grant
Role Investigator
Funding Start 2015
Funding Finish 2016
GNo G1500598
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Live cell imager for enhancement of pre-clinical cancer studies in the Hunter Translational Cancer Research Centre$25,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Conjoint Professor Stephen Ackland, Doctor Kelly Kiejda, Associate Professor Kevin Spring, Professor Xu Dong Zhang, Associate Professor Deborah Marsh, Associate Professor Christopher Scarlett, Doctor Pradeep Tanwar, Doctor Kathryn Skelding, Doctor Rick Thorne, Doctor Nikola Bowden
Scheme Equipment Grant
Role Investigator
Funding Start 2015
Funding Finish 2015
GNo G1500953
Type Of Funding Internal
Category INTE
UON Y

Familial Aspects of Cancer 2015 Research and Practice, Mantra on Salt Beach, Kingscliff, 26 - 28 August 2015$867

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding body University of Newcastle - Faculty of Health and Medicine
Project Team Doctor Kelly Kiejda
Scheme Travel Grant
Role Lead
Funding Start 2015
Funding Finish 2015
GNo G1501069
Type Of Funding Internal
Category INTE
UON Y

20142 grants / $145,199

Visualisation of microparticles for development of biomarkers and targeted drug delivery mechanisms$125,199

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Associate Professor Christopher Scarlett, Doctor Kathryn Skelding, Doctor Jude Weidenhofer, Doctor Matt Dun, Doctor Kelly Kiejda, Professor Adam McCluskey, Ms Elham Sadeqzadeh, Professor Hubert Hondermarck, Doctor Rick Thorne, Professor Rodney Scott
Scheme Research Equipment Grant
Role Investigator
Funding Start 2014
Funding Finish 2014
GNo G1400627
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

A new frontier in breast cancer: Can small molecules in the blood predict outcome?$20,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Kelly Kiejda, Doctor Jude Weidenhofer, Professor Rodney Scott
Scheme Project Grant
Role Lead
Funding Start 2014
Funding Finish 2014
GNo G1401454
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

20132 grants / $40,000

The function of the delta-40p53 isoform in breast cancer.$30,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Kelly Kiejda, Miss Brianna Morten, Professor Rodney Scott
Scheme Project Grant
Role Lead
Funding Start 2013
Funding Finish 2013
GNo G1300583
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

miRNA regulation of growth, invasion and treatment response in triple negative breast cancer$10,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Kelly Kiejda, Doctor Andrea Mathe
Scheme Project Grant
Role Lead
Funding Start 2013
Funding Finish 2013
GNo G1300728
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

20124 grants / $182,000

Small p53 isoforms, BIG implications for treatment response in breast cancer$90,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Kelly Kiejda, Professor Rodney Scott
Scheme Project Grant
Role Lead
Funding Start 2012
Funding Finish 2015
GNo G1200322
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

p53 isoforms in breast cancer - MM Sawyer Estate Scholarship$75,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Kelly Kiejda, Professor Rodney Scott
Scheme Mary Minto Sawyer Grant
Role Lead
Funding Start 2012
Funding Finish 2014
GNo G1200615
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

2011 Emerging Research Leaders Program$15,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Doctor Kelly Kiejda
Scheme Emerging Research Leaders Program
Role Lead
Funding Start 2012
Funding Finish 2012
GNo G1200817
Type Of Funding Internal
Category INTE
UON Y

Ninth International NRAi, MicroRNAs & Single Cell Biology - 2012, Hilton Garden Inn, Waltham, Massachusetts, USA, 1 - 2 May 2012$2,000

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding body University of Newcastle - Faculty of Health and Medicine
Project Team Doctor Kelly Kiejda
Scheme Travel Grant
Role Lead
Funding Start 2012
Funding Finish 2012
GNo G1200588
Type Of Funding Internal
Category INTE
UON Y

20113 grants / $50,375

p53 isoforms, a prognostic indicator in breast cancer?$45,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Kelly Kiejda, Professor Rodney Scott, Professor John Forbes
Scheme Breast Cancer Project Grant
Role Lead
Funding Start 2011
Funding Finish 2011
GNo G1001006
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

PULSE Education Prize$4,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Kelly Kiejda
Scheme PULSE Education Prize
Role Lead
Funding Start 2011
Funding Finish 2011
GNo G1001021
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Annual meeting fo the Australasian Microarray & Associated Technologies Association (AMATA), Shine Dome in Canberra, 9 - 12 October 2011$1,375

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding body University of Newcastle - Faculty of Health and Medicine
Project Team Doctor Kelly Kiejda
Scheme Travel Grant
Role Lead
Funding Start 2011
Funding Finish 2011
GNo G1100938
Type Of Funding Internal
Category INTE
UON Y

20101 grants / $21,600

The identification of microRNA's as therapeutic targets for the treatment of advanced breast cancer$21,600

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Kelly Kiejda, Professor Rodney Scott, Professor John Forbes
Scheme Research Grant
Role Lead
Funding Start 2010
Funding Finish 2010
GNo G0900144
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

20094 grants / $387,000

Targeting p53 isoforms, delta-40p53 and p53-beta, to promote chemo-sensitivity in human melanoma$272,000

Funding body: Cancer Council NSW

Funding body Cancer Council NSW
Project Team Professor Xu Dong Zhang, Conjoint Professor Peter Hersey, Doctor Kelly Kiejda
Scheme Research Grant
Role Investigator
Funding Start 2009
Funding Finish 2011
GNo G0188913
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Targeting p53 isoforms, delta-40p53 and p53-beta, to promote chemo-sensitivity in human melanoma$75,000

Funding body: Cancer Australia

Funding body Cancer Australia
Project Team Doctor Kelly Kiejda, Professor Xu Dong Zhang, Conjoint Professor Peter Hersey
Scheme Priority-driven Collaborative Cancer Research Scheme
Role Lead
Funding Start 2009
Funding Finish 2009
GNo G0188914
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Targeting p53 isoforms in human melanoma$30,000

Funding body: Calvary Mater Newcastle

Funding body Calvary Mater Newcastle
Project Team

Kelly Avery-Kiejda

Scheme Project Grant
Role Lead
Funding Start 2009
Funding Finish 2009
GNo
Type Of Funding Internal
Category INTE
UON N

The microRNA signature of endoplasmic reticulum stress in melanoma$10,000

Funding body: Calvary Mater Newcastle

Funding body Calvary Mater Newcastle
Project Team

XD Zhang

Scheme Project Grant
Role Investigator
Funding Start 2009
Funding Finish 2009
GNo
Type Of Funding Internal
Category INTE
UON N

20073 grants / $105,000

Characterization of p53 isoforms in human melanoma: do they play a role in chemoresistance?$75,000

Funding body: Cure Cancer Australia Foundation

Funding body Cure Cancer Australia Foundation
Project Team

XD Zhang

Scheme Research Grant
Role Investigator
Funding Start 2007
Funding Finish 2007
GNo
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON N

The role of p53 Isoforms in chemoresistances of human melanoma$20,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Professor Xu Dong Zhang, Doctor Kelly Kiejda
Scheme Project Grant
Role Investigator
Funding Start 2007
Funding Finish 2007
GNo G0187239
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

The role of p53 isoforms in chemoresistance of human melanoma$10,000

Funding body: Calvary Mater Newcastle

Funding body Calvary Mater Newcastle
Project Team

XD Zhang

Scheme Project Grant
Role Investigator
Funding Start 2007
Funding Finish 2007
GNo
Type Of Funding Internal
Category INTE
UON N

20061 grants / $332,000

Cameron Fellowship in Melanoma Research$332,000

Funding body: Melanoma and Skin Cancer Research Institute

Funding body Melanoma and Skin Cancer Research Institute
Project Team

Kelly Avery-Kiejda

Scheme fellowship
Role Lead
Funding Start 2006
Funding Finish 2009
GNo
Type Of Funding Internal
Category INTE
UON N

20012 grants / $82,750

Australian Postgraduate Award$64,750

Scholarship support for PhD

Funding body: Department of Education, Training & Youth Affairs

Funding body Department of Education, Training & Youth Affairs
Project Team

Kelly Avery

Scheme Scholarship support for PhD
Role Lead
Funding Start 2001
Funding Finish 2004
GNo
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON N

Millennium Foundation Stipend Enhancement Grant$18,000

Funding body: Millennium Foundation

Funding body Millennium Foundation
Project Team

Kelly Avery

Scheme Stipend enhancement grant
Role Lead
Funding Start 2001
Funding Finish 2004
GNo
Type Of Funding Not Known
Category UNKN
UON N
Edit

Research Supervision

Number of supervisions

Completed3
Current5

Total current UON EFTSL

PhD2.4

Current Supervision

Commenced Level of Study Research Title / Program / Supervisor Type
2016 PhD Genomic Assessment of the Positive Sentinel Node in Breast Cancer
PhD (Medical Genetics), Faculty of Health and Medicine, The University of Newcastle
Co-Supervisor
2015 PhD Relationship of p53ß to Breast Cancer Progression
PhD (Medical Genetics), Faculty of Health and Medicine, The University of Newcastle
Principal Supervisor
2015 PhD Circulating Exosomes in Pancreatic Cancer as a Source of Novel Diagnostic Biomarkers
PhD (Biological Sciences), Faculty of Science and Information Technology, The University of Newcastle
Co-Supervisor
2012 PhD p53 Isoforms in Breast Cancer
PhD (Medical Genetics), Faculty of Health and Medicine, The University of Newcastle
Principal Supervisor
2010 PhD The Role of Short Tandem Repeats in Genetic Susceptibility to Breast and Endometrial Cancers
PhD (Medical Genetics), Faculty of Health and Medicine, The University of Newcastle
Co-Supervisor

Past Supervision

Year Level of Study Research Title / Program / Supervisor Type
2016 PhD Genetic and Epigenetic Changes Associated with the Development of Lymph Node Metastasis in Triple Negative Breast Cancer
PhD (Medical Genetics), Faculty of Health and Medicine, The University of Newcastle
Co-Supervisor
2014 PhD The Contribution of Genetic Susceptibility to Breast Cancer
PhD (Medical Genetics), Faculty of Health and Medicine, The University of Newcastle
Co-Supervisor
2011 Honours p53 isoforms in breast cancer
Medical Science, University of Newcastle
Principal Supervisor
Edit

Dr Kelly Kiejda

Position

Research Fellow
Information Based Medicine
School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine

Focus area

Medical Genetics

Contact Details

Email kelly.kiejda@newcastle.edu.au
Phone 4042 0309
Fax 4042 0031

Office

Room Rm 3104, Lvl 3, West
Building Hunter Medical Research Institute
Location Lot 1 Kookaburra Circuit, New Lambton Heights, NSW 2305

,
Edit